AstraZeneca announced on Tuesday that US health authorities have approved Enhertu for the treatment of adults with solid tumors expressing the HER2 gene.

The biopharmaceutical group points out that the FDA's green light covers inoperable or metastatic tumors in patients who have already received treatment, but whose therapeutic options are deemed limited.

The HER2 gene is often found in solid cancer tumors such as bladder, pancreatic or ovarian cancer, but until now patients have had few treatment options, says AstraZeneca in a press release.

Enhertu, an antibody-drug conjugate specifically designed to target HER2, was already approved in the USA for the treatment of adult patients with breast cancer expressing this gene.

The product is jointly marketed by Japan's Daiichi Sankyo and AstraZeneca.

Copyright (c) 2024 CercleFinance.com. All rights reserved.